File Download

There are no files associated with this item.

  Links for fulltext
     (May Require Subscription)
Supplementary

Article: Nivolumab Plus Cabozantinib With or Without Ipilimumab for Advanced Hepatocellular Carcinoma: Results From Cohort 6 of the CheckMate 040 Trial

TitleNivolumab Plus Cabozantinib With or Without Ipilimumab for Advanced Hepatocellular Carcinoma: Results From Cohort 6 of the CheckMate 040 Trial
Authors
Yau, ThomasZagonel, VittorinaSantoro, ArmandoAcosta-Rivera, MirelisChoo, Su PinMatilla, AnaHe, Aiwu RuthCubillo, Gracian AntonioEl-Khoueiry, Anthony B.Sangro, BrunoEldawy, Tarek E.Bruix, JordiFrassineti, Giovanni LucaVaccaro, Gina M.Tschaika, MarinaScheffold, ChristianKoopmans, PetraNeely, JaclynPiscaglia, Fabio
Issue Date20-Mar-2023
PublisherAmerican Society of Clinical Oncology
Citation
Journal of Clinical Oncology, 2023, v. 41, n. 9, p. 1747-1757 How to Cite?
DOI: http://dx.doi.org/10.1200/JCO.22.00972
Persistent Identifierhttp://hdl.handle.net/10722/359724
ISSN
0732-183X
2023 Impact Factor: 42.1
2023 SCImago Journal Rankings: 10.639

 

DC FieldValueLanguage
dc.contributor.authorYau, Thomas-
dc.contributor.authorZagonel, Vittorina-
dc.contributor.authorSantoro, Armando-
dc.contributor.authorAcosta-Rivera, Mirelis-
dc.contributor.authorChoo, Su Pin-
dc.contributor.authorMatilla, Ana-
dc.contributor.authorHe, Aiwu Ruth-
dc.contributor.authorCubillo, Gracian Antonio-
dc.contributor.authorEl-Khoueiry, Anthony B.-
dc.contributor.authorSangro, Bruno-
dc.contributor.authorEldawy, Tarek E.-
dc.contributor.authorBruix, Jordi-
dc.contributor.authorFrassineti, Giovanni Luca-
dc.contributor.authorVaccaro, Gina M.-
dc.contributor.authorTschaika, Marina-
dc.contributor.authorScheffold, Christian-
dc.contributor.authorKoopmans, Petra-
dc.contributor.authorNeely, Jaclyn-
dc.contributor.authorPiscaglia, Fabio-
dc.date.accessioned2025-09-10T00:31:06Z-
dc.date.available2025-09-10T00:31:06Z-
dc.date.issued2023-03-20-
dc.identifier.citationJournal of Clinical Oncology, 2023, v. 41, n. 9, p. 1747-1757-
dc.identifier.issn0732-183X-
dc.identifier.urihttp://hdl.handle.net/10722/359724-
dc.languageeng-
dc.publisherAmerican Society of Clinical Oncology-
dc.relation.ispartofJournal of Clinical Oncology-
dc.rightsThis work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.-
dc.titleNivolumab Plus Cabozantinib With or Without Ipilimumab for Advanced Hepatocellular Carcinoma: Results From Cohort 6 of the CheckMate 040 Trial-
dc.typeArticle-
dc.identifier.doi10.1200/JCO.22.00972-
dc.identifier.volume41-
dc.identifier.issue9-
dc.identifier.spage1747-
dc.identifier.epage1757-
dc.identifier.eissn1527-7755-
dc.identifier.issnl0732-183X-

Export via OAI-PMH Interface in XML Formats

OR

Export to Other Non-XML Formats